New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
Sava Technologies today announced the first 10-day clinical evidence for its microsensor-based continuous glucose monitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results